ARVN

Arvinas is a pre-commercial biotech: its $263M of FY2025 revenue is collaboration income (Pfizer, Genentech/Roche), not product sales, and it has swung between $54M and $263M over five years — flat YoY (-0.3%) and inherently lumpy, so the top line is a partnership funding line, not a durable business. There is no approved product; the entire equity value rests on a clinical pipeline led by vepdegestrant (ER+/HER2- breast cancer), plus earlier assets ARV-102 (LRRK2/Parkinson's), ARV-806 (KRAS G12D), ARV-393 (BCL6) and ARV-027. Operations lose money at scale: -$119M operating income (-45.1% margin), -$274M operating cash flow, and $285M of R&D against a -$1.61B accumulated deficit.

The redeeming feature is the balance sheet. Debt is trivial ($0.6M total) and liabilities/equity is just 0.65x. While the cash line is only $143M, current assets are $701M against $143M current liabilities — implying roughly half a billion in short-term investments and a net-liquid position that essentially equals the entire $537M market cap. In other words, the market is assigning almost nothing to the pipeline: enterprise value is close to zero. That, plus a net loss that improved 59% YoY to -$80.8M and 7% lower share count, is what keeps this from being an outright 'avoid.'